Regeneron's Eylea still racing ahead; Strong Opsumit launch boosts Actelion forecast; Diabetes texts kept patients on meds;

> Regeneron's ($REGN) Eylea drug continues to grow by leaps and bounds, with $610 million in fourth quarter sales, up from $415 million a year ago. Report

> The Swiss drugmaker Actelion hiked its 2014 earnings forecast after its new treatment for pulmonary arterial hypertension, Opsumit, got off to a better-than-expected start. Report

> A 6 month experiment in diabetes management, using mobile communications including texts, boosted prescription costs because of better drug adherence, but saved more than $32,000 on doctor visits, ER trips and other services. Report

> Seattle Genetics ($SGEN) promoted two commercial executives--Chris Boerner, to EVP, Commercial; and Charles (Chip) Romp to SVP, Sales--and added David Fontana as VP of portfolio management and Adcetris program manager. Release

> Keryx Biopharmaceuticals brought on Greg Madison as EVP and chief operating officer; he will be charged with building a commercial organization to support the potential launch of Zerenex, a drug for kidney patients. Release

And Finally... Some doctors argue caution in using new obesity drugs from Arena Pharmaceuticals ($ARNA) and Vivus ($VVUS). Report

Suggested Articles

GSK's consumer health chief digital officer Marc Speichert was not on the stage this year at Lions Health, but meeting with potential partners.

If marketing is a persuasion business, why can’t a room full of marketing experts figure out how to change skeptics’ minds about vaccines?

China is already floating in an ocean of data, and the sea level rises every day. But these are uncharted waters—and that’s an opportunity for pharma.